Drug Profile
GSK 2862277
Alternative Names: 2862277; GSK2862277Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Antibodies
- Mechanism of Action Type 1 tumour necrosis factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute lung injury
Most Recent Events
- 23 Jul 2019 Discontinued - Phase-I for Acute lung injury (In volunteers) in United Kingdom (IV) (GlaxoSmithKline pipeline July 2019)
- 23 Jul 2019 Discontinued - Phase-II for Acute lung injury in United Kingdom (Inhalation) (GlaxoSmithKline pipeline July 2019)
- 08 Nov 2017 GlaxoSmithKline terminates a phase II trial due to protocol defined stopping criteria not met in Acute lung injury in United Kingdom (Inhalation) (NCT02221037)